Nguyen-Tran Hai, Butler Molly, Simmons Dennis, Dominguez Samuel R, Messacar Kevin
Department of Pediatrics, University of Colorado School of Medicine, 13001 E 17th Place, Aurora, CO 80045, USA.
Children's Hospital Colorado, 13123 E 16th Ave, Aurora, CO 80045, USA.
Viruses. 2025 May 5;17(5):673. doi: 10.3390/v17050673.
Enterovirus D68 (EV-D68) caused large biennial cyclical outbreaks of respiratory disease and cases of acute flaccid myelitis from 2014 to 2018 in the USA. An anticipated outbreak did not occur in 2020, likely due to non-pharmaceutical interventions targeting the COVID-19 pandemic. A large respiratory disease outbreak occurred again in 2022, but uncertainty remained regarding if circulation of EV-D68 would return to the pre-pandemic patterns. We conducted prospective active surveillance of clinical respiratory specimens from Colorado children for EV-D68 in 2023 and 2024. A subset of residual specimens positive for rhinovirus/enterovirus (RV/EV) were tested for EV-D68 via a validated in-house EV-D68 reverse transcription-PCR assay. During epi weeks 18-44 in 2023, 525 residual specimens positive for RV/EV all tested negative for EV-D68. In 2024, during epi weeks 18-44, 10 (1.8%) of the 546 RV/EV-positive specimens were EV-D68-positive. The EV-D68-positive cases were predominantly young children (median age 4.8 years) receiving treatment with asthma medications. Following the 2022 EV-D68 outbreak, an anticipated outbreak did not occur in 2023. While EV-D68 was detected in 2024, the number of cases was not as significant as in prior outbreak years. Continued surveillance for EV-D68 will be important to understand the future dynamics of EV-D68 circulation and prepare for future outbreaks.
肠道病毒D68型（EV-D68）在2014年至2018年期间在美国引发了两年一次的大规模周期性呼吸道疾病疫情以及急性弛缓性脊髓炎病例。2020年预计的疫情并未发生，可能是由于针对新冠疫情的非药物干预措施。2022年再次发生了大规模呼吸道疾病疫情，但关于EV-D68的传播是否会恢复到大流行前的模式仍存在不确定性。我们在2023年和2024年对科罗拉多州儿童的临床呼吸道标本进行了前瞻性主动监测，以检测EV-D68。通过经过验证的内部EV-D68逆转录聚合酶链反应检测法，对一部分鼻病毒/肠道病毒（RV/EV）检测呈阳性的剩余标本进行了EV-D68检测。在2023年的第18 - 44个流行周期间，525份RV/EV检测呈阳性的剩余标本的EV-D68检测均为阴性。2024年，在第18 - 44个流行周期间，546份RV/EV阳性标本中有10份（1.8%）为EV-D68阳性。EV-D68阳性病例主要是正在接受哮喘药物治疗的幼儿（中位年龄4.8岁）。在2022年EV-D68疫情之后，2023年预计的疫情并未发生。虽然2024年检测到了EV-D68，但病例数量不如之前疫情年份那么多。持续监测EV-D68对于了解其未来传播动态以及为未来疫情做准备至关重要。
